<p>/PRNewswire/ - Kent Imaging 今天就 MolecuLight Corp. 和 MolecuLight Inc. 在美國國際貿易委員會 (ITC) 提起的投訴發表聲明。該投訴指控 Kent Imaging 的 SnapshotGLO®，該產品最近獲得 FDA 510(k) 許可，侵犯了 MolecuLight 聲稱擁有許可的專利。Kent Imaging 否認投訴中所有的專利侵權指控，並對 MolecuLight 的主張毫無依據充滿信心。Kent Imaging 在創新方面的良好記錄強調了其對他人知識產權的高度尊重，並打算全力以赴、毫不妥協地捍衞自己，反對 MolecuLight 的無端指控。</p>
<p>&#34;Kent 的 Snapshot 產品線，包括 SnapshotGLO，反映了多年的嚴謹研究、專利創新以及對臨牀需求的堅定關注，&#34; Kent Imaging 首席執行官 Pierre Lemire 説。&#34;我們對我們的知識產權充滿信心，堅定我們的立場，並致力於確保臨牀醫生繼續不間斷地獲得能夠實質改善患者結果的技術。&#34;</p>
<p>隨着 SnapshotGLO 的推出，Kent Imaging 的旗艦產品 SnapshotNIR® 也在推進診斷成像，採用互補的雙模態方法。這些技術共同提升了先進傷口護理的科學性和臨牀影響，使得早期干預和治療決策的精準度得以提高。</p>
<p>Kent Imaging 繼續經歷強勁增長，投資於持續的研究和開發，目標是提供關鍵工具，幫助臨牀醫生為患者實現更好的健康結果。</p>
<p><strong>關於 Kent Imaging</strong></p>
<p>Kent Imaging 總部位於加拿大阿爾伯塔省卡爾加里，是先進診斷成像技術的領先創新者。該公司設計、製造和銷售支持傷口護理、血管和外科專業實時決策的醫療設備。通過專利技術，Kent 不斷提供突破性解決方案，支持全球醫療系統。</p>
<p>Snapshot 產品系列現在包括兩款強大的成像設備：SnapshotNIR，一種近紅外組織氧合成像設備，最初於 2017 年獲得 FDA 和加拿大衞生部的批准，並於 2025 年獲得 CE 認證；以及 SnapshotGLO，一種細菌自發熒光成像設備，於 2025 年獲得 FDA 510(k) 許可。SnapshotNIR 得到了臨牀證據的支持，證明其在增強臨牀決策中的作用，而 SnapshotGLO 則提供了對傷口生物負荷存在和分佈的實時洞察。這些 Snapshot 產品系列共同增強了臨牀醫生的檢測、指導和保護能力，促進了治療的一致性，支持了改善工作流程，併為全球更好的患者護理做出了貢獻。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SnapshotGLO® 是 Kent Imaging Inc. 的註冊商標。</td>
</tr>
<tr>
<td></td>
<td>SnapshotNIR® 是 Kent Imaging Inc. 的註冊商標。</td>
</tr>
</tbody>
</table>
<p>來源 Kent Imaging</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE5Jk5ld3NJdGVtSWQ9Q0E2NTM3NiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTkwODAwUFJfTkVXU19VU1BSX19fX19DQTY1Mzc2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE5Jk5ld3NJdGVtSWQ9Q0E2NTM3NiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTkwODAwUFJfTkVXU19VU1BSX19fX19DQTY1Mzc2"/></p>

<p>Kent Imaging 對 MolecuLight Corp. 向美國國際貿易委員會提出的關於其 SnapshotGLO® 設備的專利侵權投訴作出了回應。Kent Imaging 否認這些指控，並對其知識產權充滿信心。該公司強調其對臨牀創新的承諾，以及其 Snapshot 產品線在改善患者結果方面的重要性。Kent Imaging 繼續投資於研發，以提升傷口護理和其他醫療專業的診斷成像技術</p>

<p>, /PRNewswire/ - Kent Imaging today issued a statement regarding the complaint filed by MolecuLight Corp. and MolecuLight Inc. in the U.S. International Trade Commission (ITC). The complaint alleges that Kent Imaging's SnapshotGLO®, which recently received FDA 510(k) clearance, infringes a patent to which MolecuLight purports to have a license. Kent Imaging denies all allegations of patent infringement in the complaint and is confident that MolecuLight's claims are without merit. Underscored by its track record for innovation, Kent Imaging maintains the highest respect for the intellectual property rights of others and intends to defend itself fully and fiercely against MolecuLight's unfounded claims.</p>
<div class="lb-trans"><p>/PRNewswire/ - Kent Imaging 今天就 MolecuLight Corp. 和 MolecuLight Inc. 在美國國際貿易委員會 (ITC) 提起的投訴發表聲明。該投訴指控 Kent Imaging 的 SnapshotGLO®，該產品最近獲得 FDA 510(k) 許可，侵犯了 MolecuLight 聲稱擁有許可的專利。Kent Imaging 否認投訴中所有的專利侵權指控，並對 MolecuLight 的主張毫無依據充滿信心。Kent Imaging 在創新方面的良好記錄強調了其對他人知識產權的高度尊重，並打算全力以赴、毫不妥協地捍衞自己，反對 MolecuLight 的無端指控。</p>
</div><p>&#34;Kent's Snapshot product line, including SnapshotGLO, reflects years of disciplined research, patented innovation, and an unwavering focus on clinician needs,&#34; said Pierre Lemire, CEO, Kent Imaging. &#34;We are confident in our intellectual property, resolute in our position, and committed to ensuring clinicians continue to have uninterrupted access to technologies that materially improve patient outcomes.&#34;</p>
<div class="lb-trans"><p>&#34;Kent 的 Snapshot 產品線，包括 SnapshotGLO，反映了多年的嚴謹研究、專利創新以及對臨牀需求的堅定關注，&#34; Kent Imaging 首席執行官 Pierre Lemire 説。&#34;我們對我們的知識產權充滿信心，堅定我們的立場，並致力於確保臨牀醫生繼續不間斷地獲得能夠實質改善患者結果的技術。&#34;</p>
</div><p>With the introduction of SnapshotGLO alongside Kent Imaging's flagship product, SnapshotNIR®, Kent is advancing diagnostic imaging through a complementary, dual-modality approach. Together, these technologies elevate both the science and clinical impact of advanced wound care, enabling earlier intervention and greater precision in treatment decisions.</p>
<div class="lb-trans"><p>隨着 SnapshotGLO 的推出，Kent Imaging 的旗艦產品 SnapshotNIR® 也在推進診斷成像，採用互補的雙模態方法。這些技術共同提升了先進傷口護理的科學性和臨牀影響，使得早期干預和治療決策的精準度得以提高。</p>
</div><p>Kent Imaging continues to experience strong growth as it invests in ongoing research and development with the goal of delivering critical tools that help clinicians achieve better health outcomes for their patients.</p>
<div class="lb-trans"><p>Kent Imaging 繼續經歷強勁增長，投資於持續的研究和開發，目標是提供關鍵工具，幫助臨牀醫生為患者實現更好的健康結果。</p>
</div><p><strong>About Kent Imaging</strong></p>
<div class="lb-trans"><p><strong>關於 Kent Imaging</strong></p>
</div><p>Based in Calgary, Alberta, Canada, Kent Imaging is a leading innovator in advanced diagnostic imaging technology. The company designs, manufactures, and markets medical devices that support real-time decision-making in wound care, vascular, and surgical specialties. Through patented technologies, Kent continues to deliver groundbreaking solutions that support healthcare systems around the world.</p>
<div class="lb-trans"><p>Kent Imaging 總部位於加拿大阿爾伯塔省卡爾加里，是先進診斷成像技術的領先創新者。該公司設計、製造和銷售支持傷口護理、血管和外科專業實時決策的醫療設備。通過專利技術，Kent 不斷提供突破性解決方案，支持全球醫療系統。</p>
</div><p>The Snapshot product suite now includes two powerful imaging devices: SnapshotNIR, a near-infrared tissue oxygenation imaging device initially cleared by the FDA and Health Canada in 2017 and CE-marked in 2025; and SnapshotGLO, a bacterial autofluorescence imaging device that received FDA 510(k) clearance in 2025. SnapshotNIR is supported by clinical evidence demonstrating its role in enhancing clinical decision-making, while SnapshotGLO provides real-time insight into wound bioburden presence and distribution. Together, the Snapshot product family strengthens clinicians' ability to detect, direct, and protect—promoting treatment consistency, supporting improved workflow, and contributing to better patient care worldwide.</p>
<div class="lb-trans"><p>Snapshot 產品系列現在包括兩款強大的成像設備：SnapshotNIR，一種近紅外組織氧合成像設備，最初於 2017 年獲得 FDA 和加拿大衞生部的批准，並於 2025 年獲得 CE 認證；以及 SnapshotGLO，一種細菌自發熒光成像設備，於 2025 年獲得 FDA 510(k) 許可。SnapshotNIR 得到了臨牀證據的支持，證明其在增強臨牀決策中的作用，而 SnapshotGLO 則提供了對傷口生物負荷存在和分佈的實時洞察。這些 Snapshot 產品系列共同增強了臨牀醫生的檢測、指導和保護能力，促進了治療的一致性，支持了改善工作流程，併為全球更好的患者護理做出了貢獻。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SnapshotGLO® is a registered trademark of Kent Imaging Inc.</td>
</tr>
<tr>
<td></td>
<td>SnapshotNIR® is a registered trademark of Kent Imaging Inc.</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SnapshotGLO® 是 Kent Imaging Inc. 的註冊商標。</td>
</tr>
<tr>
<td></td>
<td>SnapshotNIR® 是 Kent Imaging Inc. 的註冊商標。</td>
</tr>
</tbody>
</table>
</div><p>SOURCE Kent Imaging</p>
<div class="lb-trans"><p>來源 Kent Imaging</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE5Jk5ld3NJdGVtSWQ9Q0E2NTM3NiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTkwODAwUFJfTkVXU19VU1BSX19fX19DQTY1Mzc2" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CA65376&amp;Transmission_Id=202601190800PR_NEWS_USPR_____CA65376&amp;DateId=20260119"/></p>

Kent Imaging 對 ITC 關於 SnapshotGLO®的投訴作出回應，並重申其對臨牀創新的承諾